Patent: Fusion Proteins for Treating Metabolic Disorders

Author(s)

Brian R. Boettcher, Novartis Institutes for BioMedical Research
Shari L. Caplan, Novartis Institutes for BioMedical Research
Douglas S. Daniels, University of DaytonFollow
Norio Hamamatsu, Novartis Institutes for BioMedical Research
Stuart Licht
Stephen Craig Weldon, Novartis Institutes for BioMedical Research

Document Type

Article

Publication Date

3-28-2013

Publication Source

U.S. Patent and Trademark Office

Abstract

The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21 associated disorders, including metabolic conditions.

Document Version

Published Version

Comments

Pub. No.: US 2013/007.9500 A1

eCommons Citation

Boettcher, Brian R.; Caplan, Shari L.; Daniels, Douglas S.; Hamamatsu, Norio; Licht, Stuart; and Weldon, Stephen Craig, "Patent: Fusion Proteins for Treating Metabolic Disorders" (2013). Chemistry Faculty Publications. 102.
https://ecommons.udayton.edu/chm_fac_pub/102